While deep brain stimulation has been successful in treating movement-related symptoms of neurological disorders like Parkinson’s disease and essential tremor, the technology hasn’t yet been widely applied to other conditions that begin in the brain. That’s beginning to change, however, as researchers have recently ramped up studies of how neurostimulators can be adapted to the much more difficult work of regulating especially complicated disorders like Alzheimer’s disease and treatment-resistant depression. So far, these studies have been launched by a range of academic institutions and devicemakers, including UCSF Health, Verily, Magnus Medical and Abbott.